← Leaderboards
William N Rom
New York University School Of Medicine
$26,662,104
Attributed
$26,662,104
Total exposure
38
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.9M · FY2005–15$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$26,915,604 · 39
By mechanism
U01$12,793,985 · 1
R01$8,769,446 · 3
T32$3,317,203 · 1
M01$1,527,970 · 32
P20$507,000 · 2
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Eric Moon-Shong M Tang$13,802,587
- Kam-Meng Tchou-Wong$3,861,790
- Xi Huang$1,006,657
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectTuberculosisHuman Therapy EvaluationDiagnostic Respiratory LavageHiv InfectionsClinical TrialsClinical Trial Phase IDrug Screening /EvaluationSputumQuestionnairesBloodCohortInterferon GammaRespiratory Disorder ChemotherapyCytokineAsbestosMycobacterium TuberculosisDiagnosisBronchoalveolar LavageMutationAids TherapyFlow CytometryCells
Grant awards (123)
NYU Lung Cancer Biomarker Center$630,061
U01 · FY2015 · CA · contact PI
NYU Lung Cancer Biomarker Center$258,397
U01 · FY2014 · CA · contact PI
NYU Lung Cancer Biomarker Center$590,723
U01 · FY2013 · CA · contact PI
Translational Research Training in Environmental Medicine$206,421
T32 · FY2013 · ES · contact PI
Longitudinal Studies of HIV-Associated Bacterial Pneumonia$175,110
R01 · FY2013 · HL · contact PI
NYU Lung Cancer Biomarker Center$895,726
U01 · FY2012 · CA · contact PI
Translational Research Training in Environmental Medicine$119,880
T32 · FY2012 · ES · contact PI
Longtitudinal Studies of HIV-Associated Bacterial Pneumonia$795,244
R01 · FY2011 · HL · contact PI
NYU Lung Cancer Biomarker Center$763,892
U01 · FY2011 · CA · contact PI
Translational Research Training in Environmental Medicine$218,392
T32 · FY2011 · ES · contact PI
NYU Lung Cancer Biomarker Center$800,160
U01 · FY2010 · CA · contact PI
Longtitudinal Studies of HIV-Associated Bacterial Pneumonia$797,912
R01 · FY2010 · HL · contact PI
Translational Research Training in Environmental Medicine$360,594
T32 · FY2010 · ES · contact PI
NYU Lung Cancer Biomarker Center$172,938
U01 · FY2010 · CA · contact PI
NYU Lung Cancer Biomarker Center$1,082,162
U01 · FY2009 · CA · contact PI
Longtitudinal Studies of HIV-Associated Bacterial Pneumonia$800,502
R01 · FY2009 · HL · contact PI
Translational Research Training in Environmental Medicine$406,274
T32 · FY2009 · ES · contact PI
NYU Lung Cancer Biomarker Center$1,060,848
U01 · FY2008 · CA · contact PI
Longtitudinal Studies of HIV-Associated Bacterial Pneumonia$803,016
R01 · FY2008 · HL · contact PI
Translational Research Training in Environmental Medicine$365,941
T32 · FY2008 · ES · contact PI
NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER FOR CANCER$41,296
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: HOST RESPONSE TO TB AND AIDS$3,182
M01 · FY2008 · RR · contact PI
PROSPECTIVE EVALUATION OF PATIENTS W/ IDIOPATHIC PULMONARY FIBROSIS-IPF REGISTRY$406
M01 · FY2008 · RR · contact PI
BRONCHOALVEOLAR LAVAGE IN ASBESTOS EXPOSED INDIVIDUALS$271
M01 · FY2008 · RR · contact PI
NYU Lung Cancer Biomarker Center$1,040,156
U01 · FY2007 · CA · contact PI
Longtitudinal Studies of HIV-Associated Bacterial Pneumonia$782,285
R01 · FY2007 · HL · contact PI
Translational Research Training in Environmental Medicine$255,351
T32 · FY2007 · ES · contact PI
NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER FOR CANCER$196,074
M01 · FY2007 · RR · contact PI
HOST RESPONSE TO TB AND AIDS$35,117
M01 · FY2007 · RR · contact PI
PROSPECTIVE EVALUATION OF PATIENTS W/ IDIOPATHIC PULMONARY FIBROSIS-IPF REGISTRY$1,578
M01 · FY2007 · RR · contact PI
NYU Lung Cancer Biomarker Center$1,049,931
U01 · FY2006 · CA · contact PI
Host Response to TB and AIDS$585,882
R01 · FY2006 · HL · contact PI
Molecular and Cell Biology in Environmental Medicine$361,476
T32 · FY2006 · ES · contact PI
New York University School of Medicine CTSA Planning Grant$253,500
P20 · FY2006 · RR · contact PI
NEW YORK UNIVERSITY SCHOOL OF MEDICINE CTSA PLANNING GRANT$253,500
P20 · FY2006 · RR · contact PI
NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER FOR CANCER$245,032
M01 · FY2006 · RR · contact PI
HOST RESPONSE TO TB AND AIDS$165,747
M01 · FY2006 · RR · contact PI
SUBCUTANEOUS INTERFERON-GAMMA FOR TB/HIV$6,685
M01 · FY2006 · RR · contact PI
PROSPECTIVE EVALUATION OF PATIENTS W/ IDIOPATHIC PULMONARY FIBROSIS-IPF REGISTRY$3,741
M01 · FY2006 · RR · contact PI
BRONCHOALVEOLAR LAVAGE IN ASBESTOS EXPOSED INDIVIDUALS$936
M01 · FY2006 · RR · contact PI
NYU Lung Cancer Biomarker Center$882,145
U01 · FY2005 · CA
Host Response to TB and AIDS$673,923
R01 · FY2005 · HL
Molecular and Cell Biology in Environmental Medicine$298,703
T32 · FY2005 · ES
NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER FOR CANCER$239,514
M01 · FY2005 · RR
BRONCHOALVEOLAR LAVAGE AND BRUSHINGS IN NORMALS$31,035
M01 · FY2005 · RR
WEEKLY RIFAPENTINE/ISONIAZID FOR 3 MON VS DAILY ISONIAZID FOR 9 MON IN LATENT TB$21,908
M01 · FY2005 · RR
PROSPECTIVE EVALUATION OF PATIENTS W/ IDIOPATHIC PULMONARY FIBROSIS-IPF REGISTRY$2,865
M01 · FY2005 · RR
HOST RESPONSE TO TB AND AIDS$2,579
M01 · FY2005 · RR
BRONCHOALVEOLAR LAVAGE IN ASBESTOS EXPOSED INDIVIDUALS$955
M01 · FY2005 · RR
MOLECULAR CHARACTERIZATION AND COURSE OF LUNG PRENEOPLASIA$477
M01 · FY2005 · RR
Host Response to TB and AIDS$610,625
R01 · FY2004 · HL
NYU Biomarker Clinical and Epidemiologic Center for Cancer$179,910
M01 · FY2004 · RR
WEEKLY RIFAPENTINE/ISONIAZID FOR 3 MON VS DAILY ISONIAZID FOR 9 MON IN LATENT TB$62,540
M01 · FY2004 · RR
Bronchoalveolar Lavage and Brushings in Normals$30,741
M01 · FY2004 · RR
A Breath Test for Lung Cancer$22,357
M01 · FY2004 · RR
Host Response To TB and AIDS$11,678
M01 · FY2004 · RR
CD8+ T-Cell Response in Resistance to TB$5,265
M01 · FY2004 · RR
Bronchoalveolar Lavage in Asbestos Exposed Individuals$2,795
M01 · FY2004 · RR
Immune Response in the Lung to TB Proteins$1,524
M01 · FY2004 · RR
Molecular Characterization and Course of Lung Preneoplas$762
M01 · FY2004 · RR
TUBERCULOSIS RESEARCH BLOOD BANK$648
M01 · FY2004 · RR
Prospective Evaluation of Patients w/ Idiopathic Pulmonary Fibrosis-IPF Registry$292
M01 · FY2004 · RR
Host Response to TB and AIDS$617,040
R01 · FY2003 · HL
NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER$1,253,944
U01 · FY2002 · CA
Host Response to TB and AIDS$635,945
R01 · FY2002 · HL
Molecular and Cell Biology in Environmental Medicine$385,359
T32 · FY2002 · ES
IMMUNE RESPONSE IN THE LUNG TO TB PROTEINS IN AIDS$330,000
R01 · FY2002 · HL
BRONCHOALVEOLAR LAVAGE IN NORMALS$0
M01 · FY2002 · RR
AEROSOLIZED INTERFERON G IN MULTIDRUG RESISTANT TUBERCULOSIS$0
M01 · FY2002 · RR
PHARMACOKINETIC SUBSTUDY OF RIFAPENTINE CLINICAL TRIAL GROUP$0
M01 · FY2002 · RR
HOST RESPONSE TO TB AND AIDS$0
M01 · FY2002 · RR
ADENOVIRAL VECTOR DELIVERY OF HS THYMIDINE KINASE GENE IN LUNG CANCER$0
M01 · FY2002 · RR
EPHEDRINE AND LOW CARBOHYDRATE DIET FOR LATE ONSET ACID MALTASE DEFICIENCY$0
M01 · FY2002 · RR
CYTOKINES AND SURFACE MOLECULES IN TUBERCULOSIS PATHOGENESIS$0
M01 · FY2002 · RR
COLCHICINE IN THE TREATMENT OF PULMONARY FIBROSIS$0
M01 · FY2002 · RR
BRONCHOALVEOLAR LAVAGE IN ASBESTOS EXPOSED INDIVIDUALS$0
M01 · FY2002 · RR
TUBERCULOSIS RESEARCH BLOOD BANK$0
M01 · FY2002 · RR
NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER$1,244,611
U01 · FY2001 · CA
IMMUNE RESPONSE IN THE LUNG TO TB PROTEINS IN AIDS$330,000
R01 · FY2001 · HL
HOST RESPONSE TO TB AND AIDS$250,981
R01 · FY2001 · HL
MOLECULAR AND CELL BIOLOGY IN ENVIRONMENTAL MEDICINE$133,255
T32 · FY2001 · ES
COLCHICINE IN THE TREATMENT OF PULMONARY FIBROSIS$0
M01 · FY2001 · RR
AEROSOLIZED INTERFERON G IN MULTIDRUG RESISTANT TUBERCULOSIS$0
M01 · FY2001 · RR
PHARMACOKINETIC SUBSTUDY OF RIFAPENTINE CLINICAL TRIAL GROUP$0
M01 · FY2001 · RR
HOST RESPONSE TO TB AND AIDS$0
M01 · FY2001 · RR
ADENOVIRAL VECTOR DELIVERY OF HS THYMIDINE KINASE GENE IN LUNG CANCER$0
M01 · FY2001 · RR
EPHEDRINE AND LOW CARBOHYDRATE DIET FOR LATE ONSET ACID MALTASE DEFICIENCY$0
M01 · FY2001 · RR
CYTOKINES AND SURFACE MOLECULES IN TUBERCULOSIS PATHOGENESIS$0
M01 · FY2001 · RR
BRONCHOALVEOLAR LAVAGE IN ASBESTOS EXPOSED INDIVIDUALS$0
M01 · FY2001 · RR
TUBERCULOSIS RESEARCH BLOOD BANK$0
M01 · FY2001 · RR
BRONCHOALVEOLAR LAVAGE IN NORMALS$0
M01 · FY2001 · RR
NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER$1,068,291
U01 · FY2000 · CA
IMMUNE RESPONSE IN THE LUNG TO TB PROTEINS IN AIDS$330,000
R01 · FY2000 · HL
HOST RESPONSE TO TB AND AIDS$250,981
R01 · FY2000 · HL
MOLECULAR AND CELL BIOLOGY IN ENVIRONMENTAL MEDICINE$205,557
T32 · FY2000 · ES
CYTOKINES AND SURFACE MOLECULES IN TUBERCULOSIS PATHOGENESIS$21,006
M01 · FY2000 · RR
HOST RESPONSE TO TB AND AIDS$21,006
M01 · FY2000 · RR
COLCHICINE IN THE TREATMENT OF PULMONARY FIBROSIS$21,006
M01 · FY2000 · RR
BRONCHOALVEOLAR LAVAGE IN ASBESTOS EXPOSED INDIVIDUALS$21,006
M01 · FY2000 · RR
BRONCHOALVEOLAR LAVAGE IN NORMALS$21,006
M01 · FY2000 · RR
TUBERCULOSIS RESEARCH BLOOD BANK$21,006
M01 · FY2000 · RR
PHARMACOKINETIC SUBSTUDY OF RIFAPENTINE CLINICAL TRIAL GROUP$21,006
M01 · FY2000 · RR
ADENOVIRAL VECTOR DELIVERY OF HS THYMIDINE KINASE GENE IN LUNG CANCER$21,006
M01 · FY2000 · RR
EPHEDRINE AND LOW CARBOHYDRATE DIET FOR LATE ONSET ACID MALTASE DEFICIENCY$21,006
M01 · FY2000 · RR
AEROSOLIZED INTERFERON G IN MULTIDRUG RESISTANT TUBERCULOSIS$21,006
M01 · FY2000 · RR
CYTOKINES AND SURFACE MOLECULES IN TUBERCULOSIS PATHOGENESIS$0
M01 · FY2000 · RR
COLCHICINE IN THE TREATMENT OF PULMONARY FIBROSIS$0
M01 · FY2000 · RR
BRONCHOALVEOLAR LAVAGE IN ASBESTOS EXPOSED INDIVIDUALS$0
M01 · FY2000 · RR
BRONCHOALVEOLAR LAVAGE IN NORMALS$0
M01 · FY2000 · RR
TUBERCULOSIS RESEARCH BLOOD BANK$0
M01 · FY2000 · RR
ISONIAZID AND RIFABUTIN IN HIV RELATED TUBERCULOSIS$0
M01 · FY2000 · RR
ISONIAZID AND RIFABUTIN IN HIV RELATED TUBERCULOSIS$0
M01 · FY2000 · RR
P53 CELL CYCLE DEREGULATION IN LUNG CANCER$0
M01 · FY2000 · RR
P53 CELL CYCLE DEREGULATION IN LUNG CANCER$0
M01 · FY2000 · RR
SHORT TERM CULTURE FILTRATE TUBERCULOSIS VACCINE TRIAL$0
M01 · FY2000 · RR
SHORT TERM CULTURE FILTRATE TUBERCULOSIS VACCINE TRIAL$0
M01 · FY2000 · RR
CD8 PLUS T CELL RESPONSE IN RESISTANCE TO TUBERCULOSIS$0
M01 · FY2000 · RR
CD8 PLUS T CELL RESPONSE IN RESISTANCE TO TUBERCULOSIS$0
M01 · FY2000 · RR
AEROSOLIZED INTERFERON G IN MULTIDRUG RESISTANT TUBERCULOSIS$0
M01 · FY2000 · RR
PHARMACOKINETIC SUBSTUDY OF RIFAPENTINE CLINICAL TRIAL GROUP$0
M01 · FY2000 · RR
HOST RESPONSE TO TB AND AIDS$0
M01 · FY2000 · RR
ADENOVIRAL VECTOR DELIVERY OF HS THYMIDINE KINASE GENE IN LUNG CANCER$0
M01 · FY2000 · RR
EPHEDRINE AND LOW CARBOHYDRATE DIET FOR LATE ONSET ACID MALTASE DEFICIENCY$0
M01 · FY2000 · RR